A 53-year-old woman was treated, after trastuzumab progression of HER2-positive metastatic disease, with capecitabine plus lapatinib and subsequently with lapatinib alone. To date, she has had persistent remission of disease since 2009.
GennariA., ConteP., RossoR., OrlandiniC., BruzziP.: Survival of metastatic breast carcinoma patients over a 20-year period: A retrospective analysis based on individual patient data from six consecutive studies. Cancer, 104: 1742–1750, 2005.
2.
SlamonD.J., Leyland-JonesB., ShakS., FuchsH., PatonV., BajamondeA., FlemingT., EiermannW., WolterJ., PegramM., BaselgaJ., NortonL.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344: 783–792, 2001.
3.
BaselgaJ., CortesJ., KimS.B., ImS.A., HeggR., ImY.H., RomanL., PedriniJ.L., PienkowskiT., KnottA., ClarkE., BenyunesM.C., RossG., SwainS.M.: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med, 366: 109–119, 2012.
4.
FountzilasG., RazisE., TsavdaridisD., KarinaM., LabropoulosS., ChristodoulouC., MavroudisD., GogasH., GeorgouliasV., SkarlosD.: Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the Hellenic Cooperative Oncology Group. Clin Breast Cancer, 4: 120–125, 2003.
5.
TripathyD., SlamonD.J., CobleighM., ArnoldA., SalehM., MortimerJ.E., MurphyM., StewartS.J.: Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol, 22: 1063–1070, 2004.
6.
GelmonK.A., MackeyJ., VermaS., GertlerS.Z., BangemannN., KlimoP., SchneeweissA., BremerK., SoulieresD., TonkinK., BellR., HeinrichB., GrenierD., DiasR.: Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer, 5: 52–58, 2004.
7.
StemmlerH.J., KahlertS., SiekieraW., UntchM., HeinrichB., HeinemannV.: Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC). Onkologie, 28: 582–586, 2005.
8.
CancelloG., MontagnaE., D'AgostinoD., GiulianoM., GiordanoA., Di LorenzoG., PlaitanoM., De PlacidoS., De LaurentiisM.: Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. Breast Cancer Res, 10: R60, 2008.
9.
ExtraJ-M, AntoineE.C., Vincent-SalomonA., DelozierT., KerbratP., Bethune-VoltersA., GuastallaJ.P., SpielmannM., MauriacL., MissetJ.L., SerinD., CamponeM., HebertC., RemblierC., BergougnouxL., CampanaF., NamerM.: Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist, 15: 779–809, 2010.
10.
MontemurroF., DonadioM., ClavarezzaM., RedanaS., JacomuzziM.E., ValabregaG., DaneseS., Vietti-RamusG., DurandoA., VenturiniM., AgliettaM.: Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist, 11: 318–324, 2006.
11.
JonesS.E.: Metastatic breast cancer: the treatment challenge. Clin Breast Cancer, 8: 224–233, 2008.
12.
Von MinckwitzG., Du BoisA., SchmidtM., MaassN., CuferT., de JonghF.E., MaartenseE., ZielinskiC., KaufmannM., BauerW., BaumannK.H., ClemensM.R., DuerrR., UleerC., AnderssonM., SteinR.C., NekljudovaV., LoiblS.: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03–05 Study. J Clin Oncol, 27: 1999–2006, 2009.
13.
Von MinckwitzG., SchwedlerK, SchmidtM., BarinoffJ., MundhenkeC., CuferT., MaartenseE., de JonghF.E., BaumannK.H., BischoffJ., HarbeckN., LückH.J., MaassN., ZielinskiC., AnderssonM., SteinR.C., NekljudovaV., LoiblS.; GBG 26/BIG 03–05 study group and participating investigators: Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3–05 phase III study in HER2-positive breast cancer. Eur J Cancer, 47: 2273–2281, 2011.
14.
BlackwellK.L., BursteinK.J., StornioloA.M., RugoH., SledgeG., KoehlerM., EllisC., CaseyM., VukeljaS., BischoffJ., BaselgaJ., O'ShaughnessyJ.: Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol, 28: 1124–1130, 2010.
15.
BlackwellK.L., BursteinK.J., StornioloA.M., RugoH.S., SledgeG., AktanG., EllisC., FloranceA., VukeljaS., BischoffJ., BaselgaJ., O'ShaughnessyJ.: Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study. J Clin Oncol, 30: 2585–2592, 2012.
16.
CarlsonR.W., TheriaultR., SchurmanC.M., RiveraE., ChungC.T., PhanS.C., ArunB., DiceK., ChivV.Y., GreenM., ValeroV.: Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. J Clin Oncol, 28: 3917–3921, 2010.
17.
CheungK.L., AgrawalA., FolkerdE., DowsettM., RobertsonJ.F., WinterbottomL.: Suppression of ovarian function in combination with an aromatase inhibitor as treatment of advanced breast cancer in premenopausal women. Eur J Cancer, 46: 2936–2942, 2010.
18.
ParkI.H., RoJ., LeeK.S., KimE.A., KwonY., NamB.H., JungS.Y., LeeS., KimS.W., KangH.S.: Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy. J Clin Oncol, 28: 2705–2711, 2010.
19.
GeyerC.E., ForsterJ., LindquistD., ChanS., RomieuC.G., PienkowskiT., Jagiello-GruszfeldA., CrownJ., ChanA., KaufmanB., SkarlosD., CamponeM., DavidsonN., BergerM., OlivaC., RubinS.D., SteinS., CameronD.: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med, 355: 2733–2743, 2006.
20.
ScaltritiM., VermaC., GuzmanM., JimenezJ., ParraJ.L., PedersenK., SmithD.J., LandolfiS., Ramon y CajalS., ArribasJ., BaselgaJ.: Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene, 28, 803–814, 2009.
21.
CameronD., CaseyM., PressM., LindquistD., PienkowskiT., RomieuC.G., ChanS., Jagiello-GruszfeldA., KaufmanB., CrownJ., ChanA., CamponeM., ViensP., DavidsonN., GorbounovaV., RaatsJ.I., SkarlosD., NewstatB., RoychowdhuryD., PaolettiP., OlivaC., RubinS., SteinS., GeyerC.E.: A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Canc Res Treat, 112: 533–543, 2008.
22.
BachelotT., RomieuG., DiérasV., CropetC., DalencF., JimenezM., Le RhunE., PiergaJ.Y., GonçalvesA., LeheurteurM., DomontJ., GutierrezM., CuréH., FerreroJ.M., Labbe-DevilliersC.: Lapatinib plus capecitabine in patients with previously untreated brain metastases form HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase II study. Lancet Oncol, 14: 64–71, 2013.
